Centenial Surgical Suture seeks probe after Rs 100.63 rise
Key highlights
- Centenial Surgical Suture said its share price reached Rs 100.63 on November 20, 2026.
- Centenial Surgical Suture said no material corporate announcement or business change supported the price movement.
- Centenial Surgical Suture asked BSE and SEBI to examine repeated buyers, possible circular trading and synchronised trades.
- The filing cites BSE scrip number 531308 on page 1 and 531380 on page 2.
powered by IRIS

CENTENIAL SURGICAL SUTURE LTD. asked BSE Limited and the Securities and Exchange Board of India, or SEBI, to investigate suspected unusual trading after its share price rose to Rs 100.63 on November 20, 2026. Centenial Surgical Suture said the increase was unsupported by a material corporate announcement or a material change in business activities.
Know Centenial Surgical Suture inside out
Results, valuation, peers and who's buying, in one view.
Why did Centenial Surgical Suture request a market probe?
Centenial Surgical Suture requested an urgent examination after observing that its share price had significantly increased to Rs 100.63 on Friday, November 20, 2026. The company sent its letter to BSE Limited's Investigation or Surveillance Department and copied SEBI, seeking a review of recent trading and price movement in its equity shares.
The company said such movements had been happening frequently, but the November 20 letter gives no previous closing price, percentage change, volume or dates for earlier movements. The filing therefore establishes the Rs 100.63 price observation and the company's concern about repeated activity, but does not allow a numerical comparison with an earlier trading session.
Centenial Surgical Suture said it had made no material announcement that could explain a significant increase or decrease in its share price. It also said there had been no material change in its business activities. On that basis, the company asked BSE and SEBI to assess whether the trades behind the November 20 movement were legally valid and genuine.
What trading patterns did Centenial Surgical Suture identify?
Centenial Surgical Suture identified repeated buyers, common persons or entities, possible circular trading and synchronised trading as patterns requiring investigation. These were the company's allegations in its November 20, 2026 letter, not findings by BSE or SEBI, and the company asked regulators to determine whether securities laws had been breached.
The company said buyers operating through brokers appeared to be spread across India and that some were repeated buyers. It also said common persons or entities appeared in purchase and sale transactions during the period when the shares rose. Centenial Surgical Suture described the activity as unnatural, highly suspicious, planned and premeditated.
Centenial Surgical Suture further alleged that a main person or entity may have prevented buyers and sellers from dealing outside a possible syndicate. It said such a pattern could involve synchronised trades among buyers or operators, as well as use of BSE's upper or lower circuit mechanism. The letter does not identify any broker, client, buyer, seller or entity, and gives no share quantities or transaction values.
Did Centenial Surgical Suture link management to the trades?
Centenial Surgical Suture stated that the company, its promoters, directors and associates had no role in the alleged misuse, unethical activity or illegal activity. The statement formed part of the November 20, 2026 request for an investigation into recent trading in its equity shares, and is the company's representation rather than a regulatory conclusion.
The company said it was ready to provide any assistance needed for a detailed investigation into probable securities-law violations. It said it had approached the authorities to protect shareholders' interests and curb activity that could adversely affect its reputation. Mahima Bathwal, company secretary and compliance officer, signed the three-page letter dated November 20, 2026.
Centenial Surgical Suture requested appropriate penal action against concerned broking houses or their clients if an investigation establishes wrongdoing. The filing does not disclose an action, notice, order, trading restriction, penalty or response from BSE or SEBI as of November 20, 2026. It reports a request for a probe, not an investigation outcome.
Got a follow-up? Ask IRIS
What does the filing disclose about the share-price movement?
Centenial Surgical Suture reported a significant increase to Rs 100.63 on November 20, 2026, but did not provide that day's opening price, previous close, intraday high, intraday low or closing price. Its comparison is qualitative: it said the movement was unsupported by a material announcement or business change and resembled frequent earlier movements.
The filing names BSE scrip number 531308 on page 1 and in its subject material. However, page 2 refers to security or scrip number 531380 while discussing a substantial rise in the price of equity shares. Centenial Surgical Suture does not explain the difference, leaving an inconsistency in the document's scrip-number references.
The mismatch does not alter the reported Rs 100.63 price observation for November 20, 2026. However, it is relevant to the administrative record because the company asked BSE and SEBI to investigate its recent equity-share trading. The company also asked the authorities, where permitted, to assess the overall pattern and alleged modus operandi rather than relying only on trade documentation.
What could regulators examine after Centenial Surgical Suture's request?
BSE and SEBI could examine the purchase and sale details that Centenial Surgical Suture said it would send or attach for the week including November 20, 2026. The company said those details would provide documentary support for its contention of possible price manipulation. No transaction-level data, broker ledger or client identity appears in the supplied three-page letter.
The company specifically asked regulators to examine whether buyers were repeated participants, whether common entities appeared on both sides of transactions, and whether circular or synchronised trading occurred. It also requested examination of possible use of BSE circuit mechanisms. Those are proposed lines of inquiry rather than confirmed explanations for the Rs 100.63 price movement.
A review could also clarify whether the intended scrip reference was 531308 or 531380. Centenial Surgical Suture requested urgent action and, if violations are established, penalties against responsible broking houses or clients. The letter provides no timetable for a regulatory decision and does not state that BSE or SEBI had opened a formal investigation by November 20, 2026.
Conclusion
Centenial Surgical Suture's November 20, 2026 filing records a request for regulatory scrutiny after it observed a share price of Rs 100.63. The company said no material announcement or business change supported the movement, while alleging possible repeated buyers, common entities, circular trading and synchronised trades. It denied involvement by the company, its promoters, directors and associates.
The next disclosed step is Centenial Surgical Suture's plan to submit or attach weekly purchase-and-sale details. Attention will be on any BSE or SEBI response, the trade records the company said it would provide, and clarification of the filing's differing references to scrip numbers 531308 and 531380.


